Design and Sample Size Determination for Multiple-dose Randomized Phase II Trials for Dose Optimization

Peng Yang,Daniel Li,Ruitao Lin,Bo Huang,Ying Yuan

DOI: https://doi.org/10.48550/arXiv.2302.09612

2023-08-30

Abstract:The conventional more-is-better dose selection paradigm, which targets the maximum tolerated dose (MTD), is not suitable for the development of targeted therapies and immunotherapies as the efficacy of these novel therapies may not increase with the dose. The U.S. Food and Drug Administration (FDA) has launched Project Optimus "to reform the dose optimization and dose selection paradigm in oncology drug development", and recently published a draft guidance on dose optimization, which outlines various approaches to achieve this goal. One highlighted approach involves conducting a randomized phase II trial following the completion of a phase I trial, where multiple doses (typically including the MTD and one or two doses lower than the MTD) are compared to identify the optimal dose that maximizes the benefit-risk tradeoff. This paper focuses on the design of such a multiple-dose randomized trial, specifically the determination of the sample size. We propose a MERIT (Multiple-dosE RandomIzed Trial design for dose optimization based on toxicity and efficacy) design that can be easily implemented with pre-calculated decision boundaries included in the protocol. We generalized the standard definitions of type I error and power to accommodate the unique characteristics of dose optimization and derived a decision rule along with an algorithm to determine the optimal sample size. Simulation studies demonstrate that the resulting MERIT design has desirable operating characteristics. To facilitate the implementation of the MERIT design, we provide software, available at <a class="link-external link-http" href="http://www.trialdesign.org" rel="external noopener nofollow">this http URL</a>.

Methodology,Applications

What problem does this paper attempt to address?

This paper attempts to address the issue of optimizing dose selection in tumor drug development. Traditionally, after determining the maximum tolerated dose (MTD) in Phase 1 clinical trials, this dose is advanced to Phase 2 and Phase 3 trials to evaluate its efficacy. However, this MTD-centric dose selection paradigm is not suitable for novel targeted therapies and immunotherapies, as the effects of these new therapies may not increase monotonically with dose, and the clinically effective dose range may not reach the MTD.

To address this challenge, the U.S. Food and Drug Administration (FDA) launched Project Optimus, aimed at reforming the dose optimization and dose selection paradigm in tumor drug development, and released a draft guidance on dose optimization. According to the FDA's recommendations, one approach is to conduct a multi-dose randomized Phase 2 trial after completing the Phase 1 dose-escalation trial, comparing multiple doses (usually including the MTD and one or two doses below the MTD) to identify the optimal biological dose (OBD) that maximizes the benefit-risk ratio.

This paper proposes a design method called MERIT (Multi-dose Randomized Trial Design Based on Toxicity and Efficacy for Dose Optimization), which is easy to implement and includes pre-calculated decision boundaries. The researchers extended the standard definitions of Type 1 error and power to accommodate the unique characteristics of dose optimization and derived decision rules and algorithms for determining the optimal sample size. Simulation studies show that the proposed MERIT design has desirable operating characteristics. To facilitate implementation, the researchers also provide software tools available at www.trialdesign.org.